US private equity (PE) giant Blackstone is understood to be exploring exit options for Japan-based Ayumi Pharmaceutical Corp, in a deal that could value the specialty pharmaceutical company at at least $1 billion.
Bloomberg was the first to report the development, saying Blackstone was working with potential advisers on options including an initial public offering and a sale.
